Sign In
Buy KPTI
$9.00
-0.230 (-2.49%)
At Close: Jun 03, 2026
Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
12:00pm, Friday, 11'th Feb 2022 Karyopharm TherapeuticsKaryopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
07:00am, Friday, 11'th Feb 2022
NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paul
Why Karyopharm Therapeutics Stock Was a Winner on Wednesday
11:43pm, Wednesday, 09'th Feb 2022 The Motley Fool
An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech's stock.
Why Karyopharm Therapeutics Stock Was a Winner on Wednesday
11:43pm, Wednesday, 09'th Feb 2022 The Motley Fool
An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech''s stock.
Why Karyopharm Therapeutics Stock Was a Winner on Wednesday
06:43pm, Wednesday, 09'th Feb 2022
An analyst upgrade that followed much better-than-expected quarterly results put some real zip into the biotech's stock.
Where Karyopharm Therapeutics Stands With Analysts
06:01pm, Wednesday, 09'th Feb 2022 Business Insider Markets
Karyopharm Therapeutics (NASDAQ: KPTI ) has observed the following analyst ratings within the last quarter:
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
03:02pm, Wednesday, 09'th Feb 2022 Benzinga
Upgrades
According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment earned $1.51 in the third qua
Karyopharm Therapeutics (KPTI) Q4 2021 Earnings Call Transcript
11:00pm, Tuesday, 08'th Feb 2022 The Motley Fool
KPTI earnings call for the period ending December 31, 2021.
Karyopharm Therapeutics (KPTI) Q4 2021 Earnings Call Transcript
11:00pm, Tuesday, 08'th Feb 2022 The Motley Fool
KPTI earnings call for the period ending December 31, 2021.
Karyopharm Therapeutics (KPTI) CEO, Richard Paulson on Q 2021 Results - Earnings Call Transcript
06:30pm, Tuesday, 08'th Feb 2022 Seeking Alpha
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2021 Earnings Conference Call February 8, 2022 8:30 am ET Company Participants Richard Paulson - President, Chief Executive Officer Sohanya…
Why Karyopharm Therapeutics Stock Is Falling Today
06:27pm, Tuesday, 08'th Feb 2022 The Motley Fool
Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing.
Why Karyopharm Therapeutics Stock Is Falling Today
06:27pm, Tuesday, 08'th Feb 2022 The Motley Fool
Fourth-quarter sales of Xpovio were encouraging, but top-line results from another trial were a little disappointing.
Karyopharm Shares Fall After Selinexor Data In Endometrial Cancer Patients
05:30pm, Tuesday, 08'th Feb 2022 Benzinga
Karyopharm Therapeutics Inc''s (NASDAQ: KPTI ) Phase 3 SIENDO selinexor study has met the primary endpoint of improved progression-free survival (PFS) as front-line maintenance therapy in advanced or recurrent endometrial cancer. Selinexor-treated patients had a median PFS of 5.7 months compared to 3.8 months for patients on placebo, representing an improvement of 50%, with a hazard ratio of 0.70 (p=0.0486), representing a 30% reduction in the risk Full story available on Benzinga.com
Karyopharm Therapeutics Inc. 2022 Q4 - Results - Earnings Call Presentation
05:11pm, Tuesday, 08'th Feb 2022 Seeking Alpha
Haemonetics, Second Sight top healthcare gainers; Pulse, Karyopharm lead losers
03:01pm, Tuesday, 08'th Feb 2022 Seeking Alpha
Haemonetics HAE +13%. Second Sight Medical Products EYES +8%. Pulse Biosciences (PLSE) -36%. Karyopharm Therapeutics KPTI -22%.
